| scholarly article | Q13442814 |
| P356 | DOI | 10.1212/WNL.44.3_PART_1.429 |
| P698 | PubMed publication ID | 8145910 |
| P2093 | author name string | O Blin | |
| G Serratrice | |||
| J Pouget | |||
| G Carles | |||
| J P Azulay | |||
| J Boucraut | |||
| F Billé-Turc | |||
| P433 | issue | 3 Pt 1 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | placebo | Q269829 |
| P304 | page(s) | 429-432 | |
| P577 | publication date | 1994-03-01 | |
| P1433 | published in | Neurology | Q1161692 |
| P1476 | title | Intravenous immunoglobulin treatment in patients with motor neuron syndromes associated with anti-GM1 antibodies: a double-blind, placebo-controlled study | |
| P478 | volume | 44 |
| Q73739726 | 79(th) ENMC International Workshop: multifocal motor neuropathy. 14-15 April 2000, Hilversum, The Netherlands |
| Q71013846 | AAEM case report #30: multifocal motor neuropathy |
| Q73445111 | Asymmetric Acquired Demyelinating Polyneuropathies: MMN and MADSAM |
| Q36142106 | Axon loss is an important determinant of weakness in multifocal motor neuropathy |
| Q73264271 | Can intravenous immunoglobulin improve antibody-mediated botulinum toxin therapy failure? |
| Q51451889 | Central motor conduction time in patients with multifocal motor conduction block. |
| Q82029191 | Chapter 12 Multifocal and other motor neuropathies |
| Q57499026 | Chapter 21 Disease-Modifying Therapies in Motor Neuron Disorders: The Present Position and Potential Future Developments |
| Q28282910 | Chronic inflammatory demyelinating polyneuropathies: current treatment strategies |
| Q73747354 | Chronic motor axonal neuropathy associated with antibodies monospecific for N-acetylgalactosaminyl GD1a |
| Q34620111 | Current proposed mechanisms of action of intravenous immunoglobulins in inflammatory neuropathies |
| Q80852673 | Diagnosis and treatment of multifocal motor neuropathy |
| Q57514502 | Differenzialdiagnose von Erkrankungen des Plexus brachialis |
| Q84316472 | Do patients having a decrease in SNAP amplitude during the course of MMN present with a different condition? |
| Q41663659 | Human immunoglobulin treatment of multifocal motor neuropathy and polyneuropathy associated with monoclonal gammopathy |
| Q36164827 | IVIg in idiopathic autoimmune neuropathies: analysis in the light of the latest results. |
| Q86421405 | Immunoglobulin (Ig) in multifocal motor neuropathy (MMN): update on evidence for Ig treatment in MMN |
| Q40371876 | Immunological findings in amyotrophic lateral sclerosis |
| Q24187418 | Immunosuppressant and immunomodulatory treatments for multifocal motor neuropathy |
| Q24200228 | Immunosuppressant and immunomodulatory treatments for multifocal motor neuropathy |
| Q24241391 | Immunosuppressant and immunomodulatory treatments for multifocal motor neuropathy |
| Q24246618 | Immunosuppressant and immunomodulatory treatments for multifocal motor neuropathy |
| Q36484418 | Immunotherapy in Peripheral Neuropathies |
| Q36332682 | Initial and long-term management of autoimmune neuropathies |
| Q55656803 | Intravenous immunoglobulin for maintenance treatment of multifocal motor neuropathy: A multi-center, open-label, 52-week phase 3 trial. |
| Q24247007 | Intravenous immunoglobulin for multifocal motor neuropathy |
| Q24247868 | Intravenous immunoglobulin for multifocal motor neuropathy |
| Q34574581 | Intravenous immunoglobulin in neurological disease: a specialist review. |
| Q36359695 | Intravenous immunoglobulin in therapy of peripheral neuropathy |
| Q71376603 | Intravenous immunoglobulin therapy in amyotrophic lateral sclerosis |
| Q36602799 | Intravenous immunoglobulin therapy in neurological diseases during pregnancy |
| Q33735178 | Intravenous immunoglobulin treatment in neurological diseases |
| Q40866049 | Intravenous immunoglobulin treatment of neurological autoimmune diseases |
| Q59413122 | La place des immunoglobulines intraveineuses en neurologie |
| Q36317538 | Long term effect of intravenous immunoglobulins and oral cyclophosphamide in multifocal motor neuropathy |
| Q33735714 | Long term follow up of multifocal motor neuropathy with conduction block under treatment |
| Q71121001 | Multifocal motor neuropathy |
| Q81679400 | Multifocal motor neuropathy |
| Q91794528 | Multifocal motor neuropathy in Austria: a nationwide survey of clinical features and response to treatment |
| Q28390264 | Multifocal motor neuropathy, multifocal acquired demyelinating sensory and motor neuropathy, and other chronic acquired demyelinating polyneuropathy variants |
| Q34204618 | Multifocal motor neuropathy. |
| Q38091664 | Multifocal motor neuropathy: current therapies and novel strategies. |
| Q37959252 | Multifocal motor neuropathy: diagnosis, pathogenesis and treatment strategies |
| Q73608375 | Normal human plasma contains antibodies that specifically block neuropathy-associated human anti-GM1 IgG-antibodies |
| Q38270717 | Optimizing IgG therapy in chronic autoimmune neuropathies: a hypothesis driven approach |
| Q34409385 | Pathogenesis and treatment of immune-mediated neuropathies |
| Q37807823 | Plasma exchange and intravenous immunoglobulins: Mechanism of action in immune-mediated neuropathies |
| Q26864907 | Rapid and reversible responses to IVIG in autoimmune neuromuscular diseases suggest mechanisms of action involving competition with functionally important autoantibodies |
| Q74028817 | Sensitivity and specificity of different conduction block criteria |
| Q36318744 | Single fibre electromyography in multifocal motor neuropathy with persistent conduction blocks |
| Q37626132 | Subcutaneous immunoglobulin: opportunities and outlook |
| Q40906180 | The current place of high-dose immunoglobulins in the treatment of neuromuscular disorders |
| Q35489630 | The effect of treatment upon temporal dispersion in IvIg responsive multifocal motor neuropathy |
| Q35537340 | The pathogenesis of multifocal motor neuropathy and an update on current management options |
| Q36602787 | Therapy of immune neuropathies with intravenous immunoglobulins |
| Q44751344 | Treatment of Churg-Strauss syndrome with high-dose intravenous immunoglobulin |
| Q73325672 | Treatment of chronic dysimmune polyneuropathies |
| Q33996087 | Treatment of chronic inflammatory demyelinating polyneuropathy |
| Q36100132 | Treatment of dys-immune neuropathies. |
| Q36880697 | Treatment of multifocal motor neuropathy with high dose intravenous immunoglobulins: a double blind, placebo controlled study |
| Q36737563 | Treatment of patients with multifocal motor neuropathy with immunoglobulins in clinical practice: the SIGNS registry |
| Q79783574 | [Long-term follow-up of multifocal motor neuropathy with conduction block under intravenous immunoglobulin] |
| Q83154743 | [Multifocal motor neuropathy with persistent conduction blocks. A chronic immune-mediated neuropathy] |
| Q80880304 | [Multifocal motor neuropathy with persistent conduction blocks: 18 years on] |
| Q73869811 | [Multifocal motor neuropathy: an individualized disease of the peripheral nervous system] |
| Q79805885 | [Recent acquisitions in the treatment of chronic immune-mediated polyneuropathies] |
| Q83179107 | [The significance of intravenous immunoglobulin in treatment of immune-mediated polyneuropathies] |
| Q80257893 | [Use of i.v. immunoglobulins in neurology. Evidence-based consensus] |
| Q72185881 | [Use of immunoglobulins G in the treatment of nervous system diseases] |
Search more.